Cai Lay Veterinary Pharmaceutical reports strong Q3 2025 profit growth

Cai Lay Veterinary Pharmaceutical Joint Stock Company recorded a net profit after tax of VND 5,689,491,204 for Q3 2025, a substantial increase from VND 1,847,324,447 in the same period of 2024. This growth of VND 3,842,166,757 is attributed to several key factors, including sales programs to stimulate demand, product diversification, enhanced sales team training, and proactive expansion of sales channels through the company’s website and social networks.

The company's revenue from sales and services for Q3 2025 reached VND 46,531,435,444, up from VND 31,966,715,610 in Q3 2024. This resulted in a gross profit of VND 14,623,674,957 for the quarter, compared to VND 11,948,574,894 in Q3 2024. Financial income also saw an increase to VND 152,271,483 from VND 146,519,482 year-over-year.

As of September 30, 2025, total assets stood at VND 117,858,568,005, an increase from VND 109,488,706,504 at the beginning of the year. Owner’s equity grew to VND 97,062,454,947 from VND 87,145,926,069. The basic earnings per share for Q3 2025 was VND 1,138, a significant rise from VND 369 in Q3 2024.